Forum (Genoa, Italy)最新文献_第2页

Guidelines for the treatment of adult intra-cranial grade II-III ependymal tumours. 成人颅内II-III级室管膜肿瘤的治疗指南。

Forum (Genoa, Italy) Pub Date : 2003-01-01

M Reni

引用次数: 0

Current and future strategies in the management of medulloblastoma in adults. 成人成神经管细胞瘤治疗的当前和未来策略。

Forum (Genoa, Italy) Pub Date : 2003-01-01

R D Kortmann, A A Brandes

引用次数: 0

Guidelines for the management and treatment of low-grade gliomas. 低级别胶质瘤的管理和治疗指南。

Forum (Genoa, Italy) Pub Date : 2003-01-01

A A Brandes, A Tosoni, R D Kortmann

引用次数: 0

Biochemotherapy of melanoma. 黑色素瘤的生物化疗。

Forum (Genoa, Italy) Pub Date : 2003-01-01

Ulrich Keilholz

引用次数: 0

Genetics of melanoma susceptibility. 黑色素瘤易感性的遗传学。

Forum (Genoa, Italy) Pub Date : 2003-01-01

Paola Ghiorzo, Giovanna Bianchi Scarrà

引用次数: 0

New drugs and combinations for malignant glioma. 治疗恶性神经胶质瘤的新药物和新组合。

Forum (Genoa, Italy) Pub Date : 2003-01-01

R Stupp, C Regg

{"title":"New drugs and combinations for malignant glioma.","authors":"R Stupp, C Regg","doi":"","DOIUrl":"","url":null,"abstract":"A new chemotherapy agent and a method for local delivery of carmustine have recently been approved for the treatment of malignant glioma. However, the increase in survival remains modest at best with only a very select patients currently benefiting truly of these treatments. Combination regimen of different alkylating agents or prior O6-alkyltransferase depletion by O6-benzylguanine or continuous temozolomide administration schedules have shown some indication for increased activity. There is preclinical rational for combining temozolomide with radiotherapy and the initial results of a phase II clinical trial were promising. Several new cytotoxic agents are currently in clinical trials in patients with recurrent glioma. More importantly, targeted therapy and antiangiogenic agents have entered the clinical development phase also for patients with glioblastoma and anaplastic astrocytoma. The optimal timing of administration of non-cytotoxic substances and their integration into the currently available treatments remains a challenge. Novel study designs and identification of surrogate markers are necessary in order to make rapid and clinically meaningful progress. This review summarises the currently available evidence of activity of the recently approved drugs against malignant glioma and mentions also agents which have failed to demonstrate a significant antitumour activity. Study endpoints are critically discussed. Combination regimens with other agents and radiation therapy are reviewed. The rational for using antiangiogenic drugs in selected ongoing trials is discussed.","PeriodicalId":79489,"journal":{"name":"Forum (Genoa, Italy)","volume":"13 1","pages":"61-75"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24172086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Guidelines for the treatment of malignant gliomas in elderly patients. 老年恶性胶质瘤的治疗指南。

Forum (Genoa, Italy) Pub Date : 2003-01-01

U Basso, A Tosoni, F Vastola, A A Brandes

{"title":"Guidelines for the treatment of malignant gliomas in elderly patients.","authors":"U Basso, A Tosoni, F Vastola, A A Brandes","doi":"","DOIUrl":"","url":null,"abstract":"More than 80% of intracranial tumours in the elderly are malignant gliomas with aggressive behaviour. Older patients have been frequently excluded from clinical trials in view of their dismal prognosis and low tolerability of chemo-radiotherapy treatments, therefore they were underrepresented in the past oncological literature. Controversies in the use and dose of RT and in the administration of chemotherapeutic agents have not been solved by the small retrospective studies conducted so far. It appears reasonable that an aggressive treatment with surgery, full dose RT and, possibly, chemotherapy should be applied to patients with good performance status, preserved cognitive functions and no relevant comorbidities, although in the absence of randomised studies the balance of benefits and side effects of integrated treatments remains controversial. Patients with low performance status and/or serious comorbidities, unable to undergo surgery, may receive a shorter RT plan, or even no treatment at all, in consideration of the rapid course of their disease which may be shorter than the hypothetical benefit of any specific treatment. Further studies should be designed to perform a reliable analysis of prognostic factors of malignant gliomas in the elderly in order to tailor treatments to each patient to obtain the best feasible benefit without compromising their quality of life.","PeriodicalId":79489,"journal":{"name":"Forum (Genoa, Italy)","volume":"13 1","pages":"46-60"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24172085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose adjuvant chemotherapy for breast cancer: state of the art. 乳腺癌高剂量辅助化疗:最新进展。

Forum (Genoa, Italy) Pub Date : 2002-01-01

Paul H Cottu, Caroline Cuvier, Marc Espié

引用次数: 0

Predictors of response to systemic therapy in breast cancer. 乳腺癌对全身治疗反应的预测因素。

Forum (Genoa, Italy) Pub Date : 2002-01-01

Alistair E Ring, Paul A Ellis

{"title":"Predictors of response to systemic therapy in breast cancer.","authors":"Alistair E Ring, Paul A Ellis","doi":"","DOIUrl":"","url":null,"abstract":"The most appropriate systemic therapy for a population of patients with breast cancer is determined from clinical trial data. However, the heterogeneity of breast cancer is such that within a population individual patients derive variable benefit. There is therefore a need for predictive molecular factors in order that treatment can be individualised. This review describes the roles of HER-2, epidermal growth factor receptor (EGFR), oestrogen receptor (ER)/progesterone receptor (PgR), Ki67, Bcl-2, p53 and gene expression profiling in predicting responses to endocrine, cytotoxic and biological therapies. ER and PgR remain the only well-established predictive markers of responses to endocrine therapy, although HER-2/neu has an emerging role in this area and in choice of adjuvant chemotherapy. There are considerable methodological difficulties in identifying useful predictive factors but on the basis of current evidence other biomarkers add little additional information. The development of targeted therapies means that the molecular targets themselves may become useful predictive factors for directing use of these therapies. HER-2 already has an established role in this area, but the role of EGFR requires further elaboration. The use of DNA microarrays to assess gene expression profiles may revolutionise our ability to predict responses to therapy.","PeriodicalId":79489,"journal":{"name":"Forum (Genoa, Italy)","volume":"12 1","pages":"19-32"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22286611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interactions of antioestrogens and aromatase inhibitors. 抗雌激素和芳香化酶抑制剂的相互作用。

Forum (Genoa, Italy) Pub Date : 2002-01-01

Peter Schmid, Kurt Possinger

{"title":"Interactions of antioestrogens and aromatase inhibitors.","authors":"Peter Schmid, Kurt Possinger","doi":"","DOIUrl":"","url":null,"abstract":"Aromatase inhibitors and antioestrogens have shown substantial activity in primary and advanced breast cancer. Since they exhibit different modes of action, attempts have been made to combine them or to use them sequentially in order to potentially increase their efficacy. In preclinical studies, combined, sequential or alternating treatments with aromatase inhibitors and antioestrogens have failed to provide higher antitumoural activity. There are relevant pharmacokinetic interactions resulting in decreased plasma concentrations of third generation aromatase inhibitors when combined with tamoxifen. Several randomised clinical trials comparing single agent and combined treatment with tamoxifen and aminoglutethimide failed to show any benefit for the combination. Early results of the adjuvant ATAC trial indicate that single agent anastrozole is superior to tamoxifen or the combination of both. Several trials are ongoing which might help to further define the role of sequential or combined treatment with aromatase inhibitors and antioestrogens. However, to date, looking at the current evidence, combined treatment with aromatase inhibitors and antioestrogens does not appear to provide additional benefit compared to single agent treatment.","PeriodicalId":79489,"journal":{"name":"Forum (Genoa, Italy)","volume":"12 1","pages":"45-59"},"PeriodicalIF":0.0,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22286613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0